Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Sep 1;202(5):635-637.
doi: 10.1164/rccm.202005-1942ED.

COVID-19 Clinical Trials: Unraveling a Methodological Gordian Knot

Alexander G Mathioudakis  1   2 , Markus Fally  3 , Rola Hashad  2   4 , Sean Knight  1   2 , Timothy Felton  1   2 , Jørgen Vestbo  1   2
Affiliations
Editorial

COVID-19 Clinical Trials: Unraveling a Methodological Gordian Knot

Alexander G Mathioudakis et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Graphical representation of the timeline to the acquisition of confident, actionable results regarding the safety and clinical effectiveness of clinical interventions for coronavirus disease (COVID-19) infection, demonstrating the benefits of conducting an interim data meta-analysis. RCT = randomized controlled trial.
See this image and copyright information in PMC

References

    1. Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020;367:1412–1413. - PubMed
    1. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al Mamun A, et al. PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2:395–404. - PMC - PubMed
    1. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. - PMC - PubMed
    1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. ACTT-1 Study Group Members. Remdesivir for the treatment of COVID-19: preliminary report. N Engl J Med. [online ahead of print] 22 May 2020; DOI: 10.1056/NEJMoa2007764. - PubMed

Publication types